2027 NCODA Global Oncology & Haematology Congress
March 10, 2027 | 9:00 AM EST
- Home
- Clinical Resources Search
- PQI: FGFR Inhibitor Side Effect Management
FGFR Inhibitor Side Effect Management
Download PQI pdf
Last Updated: September 22, 2023
By: Julia Stevens, PharmD, BCOP | Emmeline Academia, PharmD, BCOP
About this PQI
Fibroblast growth factor receptor (FGFR) inhibitors are a class of oral oncolytics approved for certain FGFR-altered malignancies, including bladder cancer (erdafitinib), cholangiocarcinoma (infigratinib and pemigatinib), and intrahepatic cholangiocarcinoma (futibatinib). FGFR inhibitors come with unique adverse effect profiles and monitoring considerations. The purpose of this PQI is to provide multidisciplinary team members with key education, monitoring, and supportive care considerations for patients on these therapies.
How to Use a Positive Quality Intervention (PQI)
Essentially, it’s a tool to improve patient care by sharing best practices in oncology care.
Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.
Find a PQIFind Similar Resources
All Resources
PQI
PQI
PQI
PQI
PQI: Beizray – An FDA-Approved Albumin Solubilized Formulation of Docetaxel
Last Updated: 11/02/2026
PQI: Retifanlimab-dlwr in Combination with CARBOplatin + PACLItaxel for the First-Line Treatment of Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal
Last Updated: 10/21/2026
PQI: Ruxolitinib Extended Release for the Management of Myelofibrosis, Polycythemia Vera, and Graft-Versus-Host Disease
Last Updated: 10/21/2026
PQI: Gedatolisib Combination Therapy for Locally Advanced or Metastatic Breast Cancer
Last Updated: 10/15/2026
PQI in Action
PQI in Action
PQI in Action
PQI in Action
PQI in Action: Inavolisib (Itovebi) Patient Management
Last Updated: 08/01/2026
PQI in Action: Revumenib (Revuforj) for the Management of Acute Leukemia
Last Updated: 06/30/2026
PQI in Action: Capivasertib (Truqap) Patient Management
Last Updated: 05/06/2026
PQI in Action: Sutimlimab-jome (Enjaymo) for the Management of Hemolysis in Cold Agglutinin Disease (CAD)
Last Updated: 04/01/2026
PQI Podcast
PQI Podcast
PQI Podcast
PQI Podcast
S11 E12: Beyond Service: Supporting Veterans and Their Families Through Cancer Care
Last Updated: 11/21/2026
S11 E13: AI Unfiltered: A Live PQI Podcast on the Future of Oncology
Last Updated: 11/21/2026
S11 E11: The Power of Connection: Building Stronger Teams and Finding Purpose
Last Updated: 11/21/2026
Bispecifics Podcast Mini Series
Last Updated: 11/21/2026
Toolkit
Toolkit
Toolkit
Toolkit
Veteran Community Care Workflow Checklist
Last Updated: 11/05/2026
VA Community Care Referral and Authorization Checklist
Last Updated: 11/05/2026
Toolkit: Simplify CLL Tracking in Oncology Practices
Last Updated: 10/15/2025
Toolkit: Optimize CLL Care in Epic
Last Updated: 10/15/2025
Treatment Support Kit
Treatment Support Kit
Treatment Support Kit
Treatment Support Kit
Treatment Support Kit: Elranatamab
Last Updated: 01/06/2026
Treatment Support Kit: Bispecific (T-Cell Engager)
Last Updated: 12/12/2025
Treatment Support Kit: Zanidatamab-hrii
Last Updated: 09/28/2025
Treatment Support Kit: Avutometinib and Defactinib
Last Updated: 08/06/2025
Video
Video
Video
Video
Video: Akynzeo® (Ready-to-Use Vial): A Step-by-Step Video Guide
Last Updated: 11/21/2026
Video: Ibrutinib-Related Cardiac Toxicities: Management & Dose Modifications
Last Updated: 11/21/2026
Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)
Last Updated: 11/21/2026
Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma
Last Updated: 11/21/2026
CAR-T
Patient Education Sheet
Patient Education Sheet
Patient Education Sheet
CAR-T Toxicities Can Move Fast. Recognition Must Move Faster
Last Updated: 09/04/2026
Filgrastim
Last Updated: 01/19/2026
Pegfilgrastim
Last Updated: 01/19/2026
Pamidronate
Last Updated: 12/15/2025